Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-Controlled Case Series Study

Wan-Ting Huang1*, Hsu-Wen Yang1, Tzu-Lin Liao1, Wan-Jen Wu1, Shu-Er Yang2, Yi-Chien Chih2, Jen-Hsiang Chuang1

1 Epidemic Intelligence Center, Taiwan Centers for Disease Control, Taipei, Taiwan. 2 Fourth Division, Taiwan Centers for Disease Control, Taipei, Taiwan.

Abstract

In Taiwan, new H1N1 monovalent vaccines without adjuvant and with MF59® adjuvant were used in the nationwide vaccination campaign beginning on November 1, 2009. From November 2009 through February 2010, the authors identified recipients of H1N1 vaccines who were diagnosed with adverse events of special interest (AESIs) in a large-linked safety database, and used the self-controlled case series (SCCS) method to examine the risk of each AESI in the 0–42 days after H1N1 vaccination. Of the 3.5 million doses of H1N1 vaccines administered and captured in the linked database, the SCCS analysis of Guillain-Barre´ syndrome (GBS) found an incidence rate ratio of 3.81 (95% confidence interval 0.43–33.85) within 0–42 days after nonadjuvanted H1N1 vaccination and no cases after MF59®-adjuvanted H1N1 vaccination. The risks of other AESIs were, in general, not increased in any of the predefined postvaccination risk periods and age groups. The databases and infrastructure created for H1N1 vaccine safety evaluation may serve as a model for safety, effectiveness and coverage studies of licensed vaccines in Taiwan.

Introduction

In June 2009, the World Health Organization declared the new influenza of swine-origin (H1N1) pandemic [1]. In Taiwan, the Advisory Committee on Immunization Practices recommended use of H1N1 vaccines in August 2009. New monovalent vaccines procured by the government and distributed to the public were inactivated vaccine without adjuvant (Adimmune Corporation, Taichung, Taiwan) for persons aged ≥1 year and MF59®-adjuvanted vaccine (Novartis Vaccines and Diagnostics, Sovicille, Italy) for persons ≥6 months [2]. The nationwide vaccination campaign started on November 1, 2009 at the peak of pandemic.

The trivalent seasonal influenza vaccine has a well-established safety record [3–6]. Multiple clinical trials assessed the immunogenicity and safety of the two H1N1 monovalent vaccines used in Taiwan, and data demonstrated that their safety profiles resembled those of the already approved seasonal influenza products [7–9]. However, because of the sample sizes of these trials, rare adverse events following immunization may not be detected until widespread use of the two vaccines in the population occurs. The importance of postlicensure safety assessment has also been demonstrated by the historical event of an increased risk of Guillain-Barré syndrome (GBS) with the receipt of the swine-origin influenza vaccine in 1976 [10].

The Taiwan government has implemented a multifaceted postlicensure safety surveillance strategy integral to its pandemic (H1N1) vaccination program [2]. The authors report the results of a population-based controlled study examining the risk of adverse events of special interest (AESIs) after H1N1 vaccination over a period of four months. Because the vaccinated and unvaccinated individuals are likely to differ in ways that are difficult to measure and control for, the analyses compare the risk of adverse events that occur during an exposed (risk) interval with events that occurred during an unexposed (control) interval of the same vaccinated person. This self-controlled case series (SCCS) analytic approach eliminates between-person confounding for a different inherent risk for these events regardless of vaccine receipt [11,12].

Materials and Methods

Ethics Statement

This study was based on a prospective active surveillance program established by the H1N1 Central Epidemic Command Center (CECC) in response to potential safety concerns to the H1N1 vaccination program [2]. According to Article 17 of the Communicable Disease Control Act (http://dohlaw.doh.gov.tw/Chi/EngDownLoad.asp?msgid=171&file=efile1) and Article 3 of the Enforcement Regulations Governing the Central Epidemic Command Center (http://dohlaw.doh.gov.tw/Chi/EngDownLoad.asp?msgid=129&file=efile1) in Taiwan, data collection for this study was conducted during the H1N1 pandemic as part of the public health response functions of the CECC for surveillance purposes and therefore, this study did not require informed consent and was not reviewed by an institutional review board. This active surveillance program collected information on personal identifiers to link the H1N1 vaccination and adverse event datasets. The linked datasets were then stripped of
Study Design
This study was conducted with automated data from a nationwide large-linked database (LLDB) developed by Taiwan Centers for Disease Control to evaluate the safety of H1N1 vaccine [2]. The LLDB linked data on demographics, H1N1 vaccinations, and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes using a unique identifier assigned to each resident. Subjects eligible for this study were those ≥6 months of age who received at least one dose of H1N1 vaccine and had an ICD-9-CM coded AESI from November 1, 2009 through February 28, 2010. The AESIs evaluated included GBS [3,6,10,14,15], demyelinating disease of the CNS [3,6,14], convulsion [4–6,14], encephalitis/myelitis [3–6,14], Bell’s palsy [3,6,14,16], acute hemorrhagic or ischemic stroke (“acute stroke”) [17], and idiopathic thrombocytopenia [6,14]. These events were selected because they are serious, biologically plausible, and have been observed in published studies or passive surveillance as a consequence of influenza vaccination. Adverse events that occurred from November 1, 2009 through February 28, 2010 were identified using one or more ICD-9-CM diagnosis codes from the NHI IC Card Data Center database (Table 1). The ICD-9-CM codes were selected from certain medical settings (outpatient, inpatient, or emergency department) in an attempt to improve specificity by limiting the definitions to the relatively severe episodes. To further separate incident events from follow-up visits for pre-existing conditions, only the first adverse event of its category to occur during the four-month study period for that individual was counted, irrespective of the timing of vaccine administration.

Identification of Exposures
Unique billing codes had been developed by NHI to reimburse the nonadjuvanted and MF59*-adjuvanted H1N1 vaccinations. These billing codes were used to collect dates and types of vaccination, along with the personal identifier, gender, and date of birth of persons who received the H1N1 vaccine from the NHI IC Card Data Center databases. For persons who received the vaccine at nontraditional settings such as schools, workplaces, and large-scale vaccination stations, the information were extracted by registrars from clinical records and manually computerized into the vaccination data [2]. As of February 28, 2010, 3.5 million (62%) of the H1N1 vaccine doses administered to the Taiwan population data had been recorded in the exposure database (Table 2).

The exposure of interest was any H1N1 vaccinations from November 1, 2009 through February 28, 2010. For each study subject, the observation period began at time of first H1N1 vaccination and ended at the earliest of February 28, 2010 or

Table 1. Adverse Events for Evaluation of Pandemic (H1N1) 2009 Monovalent Vaccine Safety.

| Adverse Event                          | ICD-9-CM Code(s) | Medical Setting |
|----------------------------------------|------------------|----------------|
| Guillain-Barre syndrome                 | 357.0            | IP             |
| Demyelinating disease of the CNS       | 340*, 341.0, 341.8, 341.9, 357.81, 377.30, 377.31, 377.32, 377.34, 377.39 | IP             |
| Convulsion                             | 345*, 780.3, 780.31, 780.39 | IP, ED         |
| Encephalitis/myelitis*                 | 323.5*, 323.6*, 323.8*, 323.9, 341.2* | IP, ED         |
| Bell’s palsy                           | 351.0            | IP, ED, OP     |
| Acute hemorrhagic or ischemic stroke   | 430*, 431*, 432*, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434* | IP, ED         |
| Idiopathic thrombocytopenia*           | 287.3, 287.31, 287.5 | IP, ED, OP     |

Abbreviation: CNS, central nervous system; ICD-9-CM, International Classification of Disease, Ninth Revision, Clinical Modification; IP, inpatient; ED, emergency department; OP, outpatient.

*Exclude if associated with any of the following within 0–7 days after encephalitis/myelitis diagnoses: 047.0, 047.1, 048, 049.0–049.8, 053–056, 058*.

A & Exclude if associated with any of the following on the same day of idiopathic thrombocytopenia diagnoses: 140*–208*, 228*, 279*, 283*, 284*, 286.6, 570*, 571*, 742.59.

Table 2. Proportion of Pandemic (H1N1) 2009 Monovalent Vaccine Doses Administered That Were Recorded in the Study Database, by Age Group, November 1, 2009–February 28, 2010.

| Age Group          | Number of Doses Administered* (n = 5,656,110) | Number of Doses Recorded (n = 3,510,461) | Percent Recorded (%) |
|--------------------|-----------------------------------------------|-----------------------------------------|----------------------|
| 6 months to 6 years| 685,289                                       | 561,461                                 | (82)                 |
| 7 to 17 years      | 2,991,018                                     | 1,838,783                               | (61)                 |
| ≥18 years          | 1,979,803                                     | 1,110,217                               | (56)                 |

*Data from National Influenza Vaccine Information System. doi:10.1371/journal.pone.0058827.t002
death. The exposed (risk) period comprised of a predefined postvaccination 43 person-days (days 0 to 42), which, at maximum, would be two exposed time periods. The unexposed (control) period was person-days of the observation period outside the exposed periods. The prevaccination person-days between November 1, 2009 and the day before the start of the observation period were not included as the control period for AESIs to avoid concerns about bias due to indication or contraindication.

### Statistical Analyses

The SCCS analyses included only individuals who were diagnosed with an AESI and had received at least one dose of H1N1 vaccine during the observation period. In this case-only method, each subject’s observation period was divided into exposed (risk) and unexposed (control) person time. Incidence rates in risk time periods were compared to those in control time periods outside of the risk periods from the same individual. This within-subject comparison was similar to a stratified analysis with each subject as a unique stratum; therefore, subjects functioned as their own controls with implicit adjustment for measured and unmeasured confounders that did not vary over time [11].

The data were manipulated and analyzed using SAS®, version 9.2 (SAS Institute Inc., Cary, NC). Conditional Poisson regression models were used to estimate the incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for each adverse event during the 0 to 42 days after vaccination by type of vaccine (nonadjuvanted and MF59®-adjuvanted). As each individual was in observation for less than four months, age was assumed not a time-varying confounder because the risk of AESIs was unlikely to vary significantly in such a relatively short time period. The AESIs were, however, stratified by age group for convulsion (0 to 7 and 8 to 42), which, at maximum, would be two exposed time periods. The unexposed (control) period was person-days of the observation period outside the exposed periods. The prevaccination person-days between November 1, 2009 and the day before the start of the observation period were not included as the control period for AESIs to avoid concerns about bias due to indication or contraindication.

### Results

A total of 3,510,461 doses of H1N1 vaccines were identified from the LLDB from November 1, 2009 through February 28, 2010, including 3,250,302 (93%) doses without adjuvant, 260,155 (7%) doses with MF59® adjuvant, and 4 (<1%) doses with unspecified vaccine type. The proportion of vaccine doses received by each age group varied (Figure 1). The majority (61%) of the nonadjuvanted monovalent vaccine were received by individuals 6–17 years of age (61%), whereas most (41%) of the MF59®-adjuvanted vaccine were received by individuals 25–49 years of age.

The recipients of H1N1 vaccine without adjuvant had 6 GBS, 12 demyelinating disease of the CNS, 1,103 convulsion, 15 encephalitis/myelitis, 414 Bell’s palsy, 849 acute stroke, and 59 idiopathic thrombocytopenia episodes identified during the study period of which 5 (83%) GBS, 5 (42%) demyelinating disease of the CNS, 497 (45%) convulsion, 10 (67%) encephalitis/myelitis, 223 (54%) Bell’s palsy, 421 (50%) acute stroke, and 32 (54%) idiopathic thrombocytopenia episodes occurred with 0–42 days after vaccination. The SCCS analyses found an increased but not statistically significant IRR of GBS (IRR 3.81, 95% CI 0.43–33.85) and encephalitis/myelitis (IRR 1.79, 95% CI 0.59–5.42) following receipt of the nonadjuvanted H1N1 vaccine. The risks of other AESIs after vaccination were generally not significantly increased in any of the predefined risk periods and age groups (Table 3). The IRR of convulsion for the 0–42 days after vaccination was significantly reduced; this effect was observed during the intervals 0–7 and 8–42 days and was independent of age (Table 3). For persons aged ≥50 years, there was a significant reduction in the risk of acute stroke at postvaccination 0–14 days (IRR 0.60, 95% CI 0.48–0.75).
No cases of GBS, demyelinating disease of the CNS, and encephalitis/myelitis were identified among recipients of MF59®-adjuvanted H1N1 vaccine. Table 4 described results from the various SCCS analyses for the exposed 0–42 days after vaccination with an MF59®-adjuvanted vaccine. The authors identified 162 convulsion, 34 Bell’s palsy, 94 acute stroke, and 9 idiopathic thrombocytopenia episodes among MF59®-adjuvanted vaccine recipients. Of these, 85 (52%) convulsion, 21 (62%) Bell’s palsy, 52 (55%) acute stroke, and 4 (44%) idiopathic thrombocytopenia episodes occurred with 0–42 days after vaccination. Immunization with the adjuvanted product was not significantly associated with increased risk of any AESI 0–42 days after vaccination. A significant reduction in the risk of convulsion for individuals aged 0–5 years in the 0–7 days (IRR 0.20, 95% CI 0.06–0.66) after vaccination was observed compared with the control period.

Table 3. Association Between Adverse Events of Special Interest and Pandemic (H1N1) 2009 Monovalent Vaccine Without Adjuvant, by Age Group and Risk Interval, November 1, 2009–February 28, 2010.

| Adverse Event                  | Age Group   | Risk Period* | Number of Cases | Person Days | IRR  (95% CI) |
|-------------------------------|-------------|--------------|-----------------|-------------|---------------|
| Guillain-Barré syndrome       | All         | 0–42         | 5               | 258         | 3.81          (0.43–33.85) |
|                               |             | Control      | 1               | 204         | (Referent)    (Referent) |
| Demyelinating disease of the CNS | All         | 0–42         | 5               | 496         | 0.56          (0.16–1.93) |
|                               |             | Control      | 7               | 490         | (Referent)    (Referent) |
| Convulsion                    | All         | 0–42         | 497             | 51,540      | 0.73          (0.64–0.82) |
|                               |             | Control      | 606             | 48,517      | (Referent)    (Referent) |
|                               | 0–5 years   | 0–7          | 34              | 3,752       | 0.67          (0.47–0.97) |
|                               |             |             | 8–42            | 15,726      | 0.63          (0.50–0.78) |
|                               |             | Control      | 231             | 18,420      | (Referent)    (Referent) |
|                               | 6 years     | 0–7          | 58              | 6,088       | 0.72          (0.54–0.95) |
|                               |             |             | 8–42            | 273         | 0.80          (0.68–0.94) |
|                               |             | Control      | 375             | 30,097      | (Referent)    (Referent) |
| Encephalitis/myelitis         | All         | 0–42         | 10              | 664         | 1.79          (0.59–5.42) |
|                               |             | Control      | 5               | 770         | (Referent)    (Referent) |
| Bell’s palsy                  | All         | 0–42         | 223             | 18,198      | 1.03          (0.84–1.25) |
|                               |             | Control      | 191             | 16,666      | (Referent)    (Referent) |
|                               | 0–24 years  | 0–14         | 36              | 3,030       | 1.03          (0.70–1.52) |
|                               |             | 15–42        | 56              | 5,539       | 0.88          (0.63–1.22) |
|                               |             | Control      | 96              | 8,417       | (Referent)    (Referent) |
|                               | 25 years    | 0–14         | 46              | 3,383       | 1.09          (0.76–1.56) |
|                               |             | 15–42        | 85              | 6,246       | 1.13          (0.84–1.52) |
|                               |             | Control      | 95              | 8,249       | (Referent)    (Referent) |
| Acute hemorrhagic or ischemic stroke | All       | 0–42         | 421             | 36,287      | 0.77          (0.67–0.89) |
|                               |             | Control      | 428             | 31,557      | (Referent)    (Referent) |
|                               | 0–49 years  | 0–14         | 16              | 1,965       | 0.58          (0.34–1.01) |
|                               |             | 15–42        | 42              | 3,593       | 0.84          (0.56–1.24) |
|                               |             | Control      | 67              | 5,109       | (Referent)    (Referent) |
|                               | 50 years    | 0–14         | 104             | 10,836      | 0.60          (0.48–0.75) |
|                               |             | 15–42        | 259             | 19,893      | 0.87          (0.74–1.03) |
|                               |             | Control      | 361             | 26,448      | (Referent)    (Referent) |
| Idiopathic thrombocytopenia   | All         | 0–42         | 32              | 2,705       | 1.09          (0.65–1.85) |
|                               |             | Control      | 27              | 2,566       | (Referent)    (Referent) |
|                               | 0–24 years  | 0–14         | 6               | 615         | 1.07          (0.41–2.85) |
|                               |             | 15–42        | 16              | 1,101       | 1.59          (0.76–3.33) |
|                               |             | Control      | 14              | 1,560       | (Referent)    (Referent) |
|                               | 25 years    | 0–14         | 4               | 345         | 0.87          (0.28–2.67) |
|                               |             | 15–42        | 6               | 644         | 0.70          (0.26–1.84) |
|                               |             | Control      | 13              | 1,006       | (Referent)    (Referent) |

Abbreviation: CNS, central nervous system; IRR, incidence rate ratio; CI, confidence interval.
*Risk (exposed) periods were days after each pandemic (H1N1) 2009 monovalent vaccination. Control (unexposed) periods were postvaccination time period outside the exposed periods.

doi:10.1371/journal.pone.0058827.t003
Discussion

The authors evaluated AESIs in Taiwan during the time that H1N1 vaccine was used [2] and did not find statistically significant increased risk of any AESI in the six weeks after vaccination. This data on H1N1 vaccine safety were strengthened by the use of a nationwide healthcare database [13] to actively identify AESIs over a defined time period and by the large number of 3.5 million vaccine doses that was studied. The use of a vaccinated cases-only approach and a within-person SCCS comparison with post-vaccination control period eliminates confounding factors that do not change during the study period, and reduces the bias due to incomplete doses capture and delayed or nonvaccination in cases with AESIs [11]. Also, the SCCS method is often more efficient in terms of power than other observation study designs and therefore, more precise estimates of effects can be made [18].

Although an elevated but nonsignificant risk of GBS after vaccination was observed, the small numbers of cases precluded any definitive conclusions on their association with H1N1 vaccines. The excess risks of approximately 1–2 cases per million doses administered in the U.S. and Canadian population-based surveillance for GBS after receipt of H1N1 vaccine [19–23] were similar to those observed after some previous seasonal influenza vaccines [15], but much lower than the 8.8 excess cases per million vaccinations observed with the use of 1976 swine influenza vaccine [10]. Antecedent respiratory infection or influenza-like illness is a recognized risk factor for GBS [24,25] and an important confounder for the association between H1N1 vaccination and GBS, as confirmed in the European case-control study [26]. The majority of monovalent H1N1 vaccinations in Taiwan occurred during the period with circulation of pandemic (H1N1) 2009 viruses [2,27]; however, the authors did not evaluate the effect of respiratory illness on the association between H1N1 vaccine and GBS in this SCCS study.

A signal of a potential association of H1N1 vaccines with Bell's palsy during the 0–42 days after vaccination has been observed by a capture-recapture evaluation of passive safety surveillance data in Taiwan [28], in which the ratio of estimated compared with expected number of cases was 1.48 (95% CI 1.11–1.98). Results of this SCCS study, however, suggested that this signal may not represent a true increased risk of Bell's palsy following immunization with either nonadjuvanted or MF59®-adjuvanted H1N1 vaccine. Bell's palsy has been linked to seasonally varying infectious, immunologic, and vascular diseases [29]. Three published studies have assessed the association between H1N1 vaccine and Bell's palsy [22,30,31]. In the Vaccine Safety Datalink study that found an excess risk of Bell's palsy in adults aged ≥25 years receiving H1N1 vaccine in the self-controlled analysis,

### Table 4. Association Between Adverse Events of Special Interesta and Pandemic (H1N1) 2009 Monovalent Vaccine Adjuvanted With MF59®, by Age Group and Risk Interval, November 1, 2009–February 28, 2010.

| Adverse Event | Age Group | Risk Periodb | Number of Cases | Person Days | IRRc (95% CI) |
|---------------|-----------|---------------|-----------------|-------------|--------------|
| Convulsion    | All       | 0–42          | 85              | 7,803       | 0.89 (0.63–1.24) |
|               | Control   | 77            | 7,246           | (Referent)  | (Referent)   |
|               | 0–5 years | 0–7           | 3               | 1,192       | 0.20 (0.06–0.66) |
|               |           | 8–42          | 54              | 4,894       | 0.90 (0.61–1.33) |
|               | Control   | 63            | 5,634           | (Referent)  | (Referent)   |
|               | 0–7       | 6             | 333             | 1.32        | (0.45–3.86) |
|               | 8–42      | 22            | 1,384           | 1.46        | (0.71–3.00) |
|               | Control   | 14            | 1,612           | (Referent)  | (Referent)   |
| Bell's palsy  | All       | 0–42          | 21              | 1,485       | 0.92 (0.43–2.00) |
|               | Control   | 13            | 1,154           | (Referent)  | (Referent)   |
|               | ≥25 years | 0–14          | 8               | 435         | 1.24 (0.45–3.38) |
|               |           | 15–42         | 11              | 807         | 0.92 (0.35–2.35) |
|               | Control   | 10            | 928             | (Referent)  | (Referent)   |
| Acute hemorrhagic or ischemic stroke | All | 0–42 | 52 | 3,974 | 1.02 (0.66–1.58) |
|               | Control   | 42            | 4,029           | (Referent)  | (Referent)   |
|               | 0–49 years| 0–14          | 4               | 345         | 0.99 (0.31–3.22) |
|               |           | 15–42         | 7               | 636         | 0.96 (0.36–2.54) |
|               | Control   | 12            | 1,227           | (Referent)  | (Referent)   |
|               | ≥50 years | 0–14          | 18              | 1,061       | 1.24 (0.66–2.31) |
|               |           | 15–42         | 23              | 1,932       | 0.93 (0.52–1.64) |
|               | Control   | 30            | 2,802           | (Referent)  | (Referent)   |
| Idiopathic thrombocytopenia | All | 0–42 | 4 | 426 | 0.56 (0.13–2.36) |
|               | Control   | 5             | 361             | (Referent)  | (Referent)   |

Abbreviation: CNS, central nervous system; IRR, incidence rate ratio; CI, confidence interval.

aNo cases of Guillain-Barre syndrome, demyelinating disease of the CNS, and encephalitis/myelitis occurred among recipients of MF59®-adjuvanted vaccine.

bRisk (exposed) periods were days after each pandemic (H1N1) 2009 monovalent vaccination. Control (unexposed) periods were postvaccination time period outside the exposed periods.

cAnalyses were performed if at least three exposed cases were available.

doi:10.1371/journal.pone.0058827.t004
further assessment by using the case-centered approach to minimize confounding by seasonality observed no association [30]. In other studies, a small excess risk for Bell's palsy was either observed only in comorbid persons who were targeted for H1N1 vaccination [31], or their evaluations did not control for seasonality of vaccination and disease [22,31].

The findings that a reduction in the risk of AESI, particularly convulsion and acute stroke, was observed in some postvaccination time periods should be interpreted with caution. One possible explanation is that influenza infection is associated with major neurologic and vascular morbidities [17,32], and vaccination averts H1N1 infection and associated morbidities. The authors, however, did not collect data on H1N1 infection and were unable to explore whether the beneficial effects of vaccination observed in this study were due to prevented influenza illness. An alternative explanation is confounding. Vaccination is often postponed for medical illness and individuals tend to receive a vaccine in a relatively healthy condition. The H1N1 vaccine may appear to be protective for any conditions that occur in the immediate time period after vaccination because fewer healthcare visits would be expected [33,34]. For some AESIs evaluated in this study, the presence of this “healthy vaccinee effect” was suggested by a lower IRR for risk period that began at time of H1N1 vaccination compared with adjacent risk period that began at an interval of 8 or 15 days after vaccination. Also, a decrease in risk in this immediate postvaccination period was unlikely due to vaccination averting influenza disease and associated morbidity because recipients developed peak antibody protection against influenza infection two weeks after vaccination [7–9].

There were several additional limitations of the study. First, the adverse events were identified through ICD-9-CM codes and not validated against medical records. Use of ICD-9-CM codes would miss events that were not coded for, or the event status could be misclassified. The computerized data did not have information on the date of event onset but rather, the date of visit or admission was used. Insidious events could have variable lag time between symptom onset and medical attendance; their occurrences would be nondifferentially misclassified with respect to risk or control periods, which was likely to bias the IRR estimation toward unity. Second, because the capture of H1N1 vaccinations was only 62%, absence of H1N1 vaccination records in the LLDB, particularly for individuals ≥18 years of age and those received in non-traditional settings, did not necessarily indicate no vaccination [2]. The results from analyzing only cases with vaccination records in the LLDB might not be representative of H1N1 vaccine recipients. Furthermore, an individual’s postvaccination risk period could be misclassified as unexposed (control period) if a second dose of H1N1 vaccine was administered but not computerized into the exposure database. Third, the SCOS method controlled for confounders that did not vary over the observation period [11] but did not adjust for time-varying confounders. Other types of routine vaccines, for example, measles, mumps, and rubella vaccine and the 13-valent pneumococcal conjugate vaccine, were known to be associated with an increased risk of the prespecified adverse events (e.g., febrile convolution or idiopathic thrombocytopenial [35,36], but their administrations were neither collected for evaluation as potential confounders in this study. Finally, even with a complete capture of 5.6 million H1N1 vaccine doses administered during the study period, there was limited statistical power to detect a very rare outcome such as GBS, if the excess risk associated with vaccine receipt is relatively small. The precise assessment of risk would require a larger population of subjects by pooling data through a regional or international collaboration.

In conclusion, the authors conducted safety evaluations of H1N1 monovalent vaccines in Taiwan and found no significantly increased risk of prespecified AESIs after receipt of either nonadjuvanted or MF59®-adjuvanted product. The possible association of GBS following nonadjuvanted H1N1 vaccine, although not statistically significant, was consistent with published studies in which a small excess risk was observed [19–21,23]. As new vaccines are introduced and new recommendations are issued, it is desirable for countries to develop hypothesis-testing capacity to respond to potential safety concerns. The databases and infrastructures used in this H1N1 vaccine safety evaluation may serve as a model for safety, effectiveness and coverage studies of other licensed vaccines in Taiwan.

Acknowledgments

Disclaimer: Preliminary results of this work were presented at the 45th Annual Meeting of the Infectious Diseases Society of America, October 21–24, 2010, Vancouver, British Columbia, Canada.

Author Contributions

Conceived and designed the experiments: WTH YCC JHC. Performed the experiments: WTH HWJ TLL WJW. Analyzed the data: WTH HWJ TLL WJW. Contributed reagents/materials/analysis tools: WTH HWJ TLL WJW. Wrote the paper: WTH HWJ TLL WJW YCC JHC.

References

1. World Health Organization (2009) New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 84: 249–257.
2. Huang WT, Chen WW, Yang HW, Chen WC, Chao YN, et al. (2016) Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan. Vaccine 28: 7161–7166.
3. Vellozzi C, Burwen DR, Dohovdacz A, Ball R, Walton K, et al. (2009) Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 27: 2114–2120.
4. McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, et al. (2005) Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the Vaccine Adverse Event Reporting System, 1990–2003. Pediatrics 115: 453–460.
5. Hambridge S, Glanz J, France E, McClure D, Xu S, et al. (2006) Safety of trivalent inactivated influenza vaccine in children 6–23 months old. JAMA 296: 1990–1997.
6. Greene SK, Kullendorf D, Lewis EM, Li R, Yin R, et al. (2010) Near realtime surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 171: 177–188.
7. Kung HC, Huang KG, Kao TM, Lee YC, Chang F, et al. (2010) A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. Vaccine 28: 7357–7363.
8. Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, et al. (2010) Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 28: 5084–5070.
9. Clark TW, Pareek M, Hosh切尔 K, Dillon H, Nicholson KG, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59®-adjuvanted vaccine. New Engl J Med 361: 2424–2435.
10. Schonberger LB, Bregman DJ, Sullivan-Bolyai JE, Keenlyside RA, Ziegler DW, et al. (1979) Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 110: 105–123.
11. Whitaker HJ, Farrington CP, Spiebers B, Muozenda P (2006) Tutorial in biostatistics: the self-controlled case series method. Stat Med 25: 1768–1797.
12. Jackson ML, Nelson JC, Weis NS, Neu Серг KM, Barlow W, et al. (2008) Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 372: 398–405.
13. Bureau of National Health Insurance, National Health Insurance in Taiwan 2011 Annual Report. Available: http://www.nhi.gov.tw/Resource/webdata/13767_1_NHI%20IN%20TAIWAN%202011%20ANNUAL%20REPORT.pdf. Accessed 17 September 2012.
14. Black S, Eksoda J, Siegert CA, Halsey N, MacDonald N, et al. (2009) Importance of background rates of disease in assessment of vaccine safety during
mass immunization with pandemic H1N1 influenza vaccines. Lancet 374: 2115–2122.

15. Lasky T, Terracciano GJ, Magder L, Kosci CL, Ballesteros M, et al. (1998) The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339: 1797–1802.

16. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, et al. (2004) A potential signal of Bell’s palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) – United States, 1991–2001. Pharmacoepidemiol Drug Saf 13: 505–510.

17. Smeech L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351: 2611–2618.

18. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, et al. (2006) Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol 59: 688–698.

19. Tokars JI, Lewis P, DeStefano F, Wise M, Viray M, et al. (2012) The risk of Guillain-Barré syndrome following receipt of monovalent inactivated influenza A (H1N1) 2009 monovalent vaccine and 2009–2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf 21: 546–552.

20. Greene SK, Rett M, Weintraub ES, Li L, Yin R, et al. (2012) Risk of confirmed Guillain-Barré syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009–2010. Am J Epidemiol 175: 1100–1109.

21. Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, et al. (2012) Guillain-Barré syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol 175: 1110–1119.

22. Yih WK, Lee GM, Lieu TA, Ball R, Kulldorff M, et al. (2012) Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009–2010. Am J Epidemiol 175: 1120–1128.

23. De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, et al. (2012) Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA 308: 175–81.

24. Stone J, Andrews N, Wise L, Miller E (2009) Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 169: 382–388.

25. Grimoldi-Bensouda I, Alperovitch A, Besson G, Vial C, Cuisnet GM, et al. (2011) Guillain-Barré syndrome, influenza-like illness, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol 174: 326–335.

26. Dieleman J, Romio S, Johansen K, Weihe D, Bohnheffer J, et al. (2013) Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 343: d9308. DOI: 10.1136/bmj.d9308.

27. Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, et al. (2012) Nationwide surveillance of influenza during the pandemic (2009–10) and postpandemic (2010–11) periods in Taiwan. PLoS One 7: e36120.

28. Huang WT, Huang WI, Huang YW, Hsu CW, Chuang JH (2012) The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis. Vaccine 30: 2168–2172.

29. Campbell KE, Brundage JP (2002) Effects of climate, latitude, and season on the incidence of Bell’s palsy in the US Armed Forces, October 1998 to September 1999. Am J Epidemiol 156: 32–39.

30. Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, et al. (2011) H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink project. Am J Prev Med 41: 121–120.

31. Bardage C, Persson I, Otrupjot A, Bergman U, Ladvigsson JE, et al. (2011) Neurological and autoimmune disorders after vaccination against pandemic influenza A(H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 343: d5956. DOI: 10.1136/bmj.d5956.

32. Glaser CA, Winter K, DuBray K, Harriman K, Uyeki TM, et al. (2012) A population-based study of neurologic manifestations of severe influenza A/H1N1pdm09 in California. Clin Infect Dis 55: 514–520.

33. Fine PEM, Chen RT (1992) Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 136: 121–135.

34. Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, et al. (2012) Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. In press. DOI: 10.1016/j.vaccine.2012.07.024.

35. Farrington P, Pugh S, Colville A, Flower A, Nash J, et al. (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345: 567–569.

36. Tsie A, Tseng HF, Greene SK, Vehou C, Lee GM, et al. (2012) Signal detection and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010–2011. Vaccine 30: 2024–2031.